Explore: Valvulopathy

Press. ISBN 9780849388095. Elangbam CS (October 2010). "Drug-induced valvulopathy: an update". Toxicologic Pathology. 38 (6): 837–48. CiteSeerX 10.1.1

5-HT2B receptor is a well-known antitarget and is associated with cardiac valvulopathy. However, not all 5-HT2B receptor agonists, for instance ropinirole,

of the serotonin 5-HT2B receptor and has been associated with cardiac valvulopathy. Despite acting as a potent serotonin 5-HT2A receptor agonist, ergotamine

receptor, bromocriptine has been said not to pose a risk of cardiac valvulopathy. This is in contrast to other ergolines acting instead as 5-HT2B receptor

acts as an antagonist. Cabergoline has been associated with cardiac valvulopathy due to activation of 5-HT2B receptors. Ergot derivatives like cabergoline

agonism at this receptor and does not appear to pose a risk of cardiac valvulopathy. Ropinirole is metabolized primarily by cytochrome P450 CYP1A2 to form

Mitral Valve Prolapse murmur Heart sounds of a 16-year-old girl diagnosed with mitral valve prolapse and mitral regurgitation. Auscultating her heart,

in the central nervous system. MDMA may increase the risk of cardiac valvulopathy in heavy or long-term users due to activation of serotonin 5-HT2B receptors

migraines or cluster headaches. This is due to toxicity, such as cardiac valvulopathy, which was first reported with long-term use in the late 1960s. Ergot-based

use of LSD and other serotonergic psychedelics is cardiac fibrosis and valvulopathy due to serotonin 5-HT2B receptor agonism. This may also be the case with